Indaptus Therapeutics Inc. (NASDAQ: INDP) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT INDAPTUS THERAPEUTICS INC.

Indaptus Therapeutics Inc. (NASDAQ: INDP)
Listen to this Section


$3.11
+0.8950 ( +40.50% ) 707.1K

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Market Data


Open $3.11
Previous Close $2.21
Volume 707.1K
Market Cap $250.27M
Day Range $2.13 - $3.14
52 Week Range $0.92 - $19.91
Shares Outstanding 113.24M
Change % +40.50%
Net Change ▲ 0.8950
Insider Ownership -0.05%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2021
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -556,328.00

Date Type Amount Purchased Purchaser
2024-08-08 Sale -84932.00 Meckler Jeffrey A
2024-06-07 Sale -12500.00 Hayes William B
2024-06-07 Sale -30000.00 Pomerantz Roger
2024-06-07 Sale -12500.00 MADDALUNA ANTHONY J
2024-06-07 Sale -12500.00 Gilbert Mark John
2024-06-07 Sale -12500.00 Martell Robert
2024-06-07 Sale -12500.00 Karah Hila
2024-01-23 Sale -75000.00 Linscott Walt Addison
2024-01-23 Sale -75000.00 Waltzman Roger J.
2024-01-23 Sale -40000.00 Sassi Nir

SEC Filings


Form Type Description Pages Date
8-k 8K-related 14 Nov 12, 2025
10-q Quarterly Reports 60 Nov 12, 2025
8-k 8K-related 14 Sep 04, 2025
10-q Quarterly Reports 62 Aug 13, 2025
8-k 8K-related 14 Aug 13, 2025
8-k 8K-related 12 Jul 29, 2025
4 Insider transactions 1 Jul 29, 2025
8-k 8K-related 12 Jul 16, 2025
8-k 8K-related 15 Jul 01, 2025
8-k 8K-related 15 Jun 26, 2025

Latest News


× Before browsing our site, please accept our cookies policy